Statins, but not proprotein convertase subtilisin‐kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low‐density lipoprotein receptor upregulation

Documenti analoghi

• Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin/kexin type 9/low density lipoprotein receptor pathway
  di: Fengyuan Lu, et al.
  Pubblicazione: (2025)
• Regression of carotid atherosclerosis in high‐risk individuals with proprotein convertase subtilisin/kexin type 9 inhibitors
  di: Albert Z. Luu, et al.
  Pubblicazione: (2025)
• Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
  di: Hongyan Jiang, et al.
  Pubblicazione: (2024)
• Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9
  di: Alexander M. Cao Zhang, et al.
  Pubblicazione: (2024)
• Extracellular vesicle‐mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin‐kexin type 9 (Pcsk9) in primary mouse hepatocytes
  di: Nazma F. Ilahibaks, et al.
  Pubblicazione: (2024)